Dolutegravir/Lamivudine (Dovato®)

Assessment Status Rapid Review Complete
Drug Dolutegravir/lamivudine
Brand Dovato®
Indication For the treatment of Human Immunodeficiency Virus type 1 (HIV-1) infection in adults and adolescents above 12 years of age weighing at least 40kg, with no known or suspected resistance to the integrase inhibitor class, or lamivudine.
Assessment Process
Rapid review commissioned 16/07/2019
Rapid review completed 26/08/2019
Rapid review outcome A full HTA is not recommended. The NCPE recommend that dolutegravir /lamivudine (Dovato®) not be considered for reimbursement at the submitted price.*

* This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods Act) 2013.

The HSE has approved reimbursement following confidential price negotiations; December 2019